$1.440
-0.048 (-3.36%)Al cierre
Noticias de FBLG
Eventos de FBLG
FibroBiologics Secures U.S. Patent No. 12,691,147
FibroBiologics announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,691,147, entitled "Methods and Compositions for Treatment of Type 1 Diabetes Using Fibroblasts in Facilitation of Islet Engraftment." The patent describes methods utilizing fibroblasts to improve the engraftment and long-term function of transplanted pancreatic islets, addressing one of the major challenges in islet transplantation.
FibroBiologics Granted European Patent EP 3043825 B1
FibroBiologics announced that the European Patent Office, or EPO, has granted the Company's patent entitled "Gene Therapy for the Regeneration of Chondrocytes or Cartilage Type Cells." The granted patent, European Patent No. EP 3043825 B1, contains 12 claims directed to compositions comprising one or more expression vectors encoding therapeutic polynucleotides, including Sox9, for use in treating individuals in need of cartilage repair. The patent will be validated across selected designated contracting states of the European Patent Convention, extending the Company's protection for this technology into major European markets. Some of the granted claims include: Compositions comprising one or more expression vectors encoding therapeutic polynucleotides that include Sox9, for use in producing chondrocytes or cartilage-type cells in the joint of an individual in need of cartilage repair; Delivery of those expression vectors to fibroblast cells, which then differentiate into chondrocytes or cartilage-type cells, either before or after delivery to the joint; Use of viral and non-viral vectors for genetic modification; Combinations of Sox9 with additional therapeutic genes on a single or multiple vectors.
FibroBiologics Files to Sell Up to 12.53M Shares of Common Stock
FibroBiologics files to sell up to 12.53M shares of common stock
FibroBiologics Appoints Dr. Kathleen Rubins to Board of Directors
FibroBiologics announced the appointment of Kathleen "Kate" Rubins, Ph.D. to its Board of Directors. As a retired NASA astronaut, microbiologist, and genomics scientist, Dr. Rubins has conducted pioneering medical research on the immune response to infection at high-profile academic institutions and pioneered molecular, cellular, and genomic techniques for human health on board the International Space Station.
FibroBiologics Completes Manufacturing of Third Batch of CYWC628
FibroBiologics announced completion of manufacturing of the third batch of its CYWC628 drug product for the ongoing Phase 1/2 clinical trial in patients with diabetic foot ulcers, DFUs. The batch was manufactured in accordance with cGMP standards and is undergoing the required safety and quality testing ahead of release for clinical use. Upon release of the third batch, FibroBiologics expects to have sufficient drug product to complete the DFU clinical trial.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.